EMS Acarbose
Phase 3Small molecule
EMS Acarbose is one of 64 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
EMS Acarbose
EEMS
Phase 3
Tanzeum
GSKPreclinical
Insulin 320
Novo NordiskPreclinical
NOVOLIN R
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
Golytely
BayerPreclinical
Cipro
BayerPreclinical
Myrbetriq
AstellasPreclinical
Lantus
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Allergic Rhinitis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EMS Acarbose. EMBL-EBI & Wellcome Sanger Institute.
- [4]